Modalis Therapeutics Corp
TSE:4883
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Modalis Therapeutics Corp
TSE:4883
|
JP |
|
S
|
Shandong Xinchao Energy Corp Ltd
SSE:600777
|
CN |
|
B
|
Bersama Mencapai Puncak PT Tbk
IDX:BAIK
|
ID |
|
R
|
RealNetworks Inc
F:RNWA
|
US |
|
Kakatiya Cement Sugar and Industries Ltd
NSE:KAKATCEM
|
IN |
|
A
|
Akva Group ASA
OSE:AKVA
|
NO |
|
M
|
Mercedes Benz Group AG
SWB:MBG
|
DE |
|
H
|
Hatsun Agro Product Ltd
BSE:531531
|
IN |
|
A
|
AK Alrosa PAO
MOEX:ALRS
|
RU |
|
Kratos Defense and Security Solutions Inc
NASDAQ:KTOS
|
US |
|
G
|
Greatland Gold PLC
ASX:GGP
|
AU |
|
CT Vision SL (International) Holdings Ltd
HKEX:994
|
HK |
|
TV Tokyo Holdings Corp
TSE:9413
|
JP |
|
Aifarm Ltd
OTC:AIFM
|
US |
|
Styland Holdings Ltd
HKEX:211
|
HK |
|
Anixa Biosciences Inc
NASDAQ:ANIX
|
US |
|
Blue Owl Capital Corp
NYSE:OBDC
|
US |
|
Ontrak Inc
NASDAQ:OTRK
|
US |
|
E1 Corp
KRX:017940
|
KR |
Modalis Therapeutics Corp
Modalis Therapeutics Corp. engages in the development of gene therapy drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 26 full-time employees. The company went IPO on 2020-08-03. The firm develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The firm has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The firm's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Modalis Therapeutics Corp. engages in the development of gene therapy drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 26 full-time employees. The company went IPO on 2020-08-03. The firm develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The firm has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The firm's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
